Search
Simulations Plus Inc
SLPAdd to Watchlist
18.390USD
+0.040+0.22%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
370.50MMarket Cap
LossP/E TTM
More Details of Simulations Plus Inc Company
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
Simulations Plus Inc Info
Ticker SymbolSLP
Company nameSimulations Plus Inc
IPO dateJun 18, 1997
CEOO'Connor (Shawn M)
Number of employees212
Security typeOrdinary Share
Fiscal year-endJun 18
Address800 Park Offices Drive, Suite 401
CityRESEARCH TRIANGLE PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27709
Phone16617237723
Websitehttps://www.simulations-plus.com/
Ticker SymbolSLP
IPO dateJun 18, 1997
CEOO'Connor (Shawn M)
Company Executives of Simulations Plus Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Independent Director
3.25M
-0.46%
Ms. Jill Fiedler-Kelly
Ms. Jill Fiedler-Kelly
Interim President - Services Solutions
Interim President - Services Solutions
77.82K
--
Ms. Sharlene Evans
Ms. Sharlene Evans
Independent Director
Independent Director
17.17K
+12.33%
Dr. John Kenneth Paglia, Ph.D.
Dr. John Kenneth Paglia, Ph.D.
Independent Director
Independent Director
14.59K
+14.51%
Ms. Jenna Rouse
Ms. Jenna Rouse
Global Head - Clinical Operations
Global Head - Clinical Operations
--
--
Mr. Murry Alper
Mr. Murry Alper
Global Head - Medical Communications
Global Head - Medical Communications
--
--
Ms. Lisa Fortuna
Ms. Lisa Fortuna
Investor Relations
Investor Relations
--
--
Mr. Josh Fohey
Mr. Josh Fohey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Erik Guffrey
Mr. Erik Guffrey
Co-Chief Product and Technology Officer
Co-Chief Product and Technology Officer
--
--
Mr. John A. Dibella
Mr. John A. Dibella
Chief Revenue Officer
Chief Revenue Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Independent Director
3.25M
-0.46%
Ms. Jill Fiedler-Kelly
Ms. Jill Fiedler-Kelly
Interim President - Services Solutions
Interim President - Services Solutions
77.82K
--
Ms. Sharlene Evans
Ms. Sharlene Evans
Independent Director
Independent Director
17.17K
+12.33%
Dr. John Kenneth Paglia, Ph.D.
Dr. John Kenneth Paglia, Ph.D.
Independent Director
Independent Director
14.59K
+14.51%
Ms. Jenna Rouse
Ms. Jenna Rouse
Global Head - Clinical Operations
Global Head - Clinical Operations
--
--
Mr. Murry Alper
Mr. Murry Alper
Global Head - Medical Communications
Global Head - Medical Communications
--
--
FAQs
Who are the top five shareholders of Simulations Plus Inc?
The top five shareholders of Simulations Plus Inc are: Dr. Hon. Walter S. Woltosz
How many institutions hold shares of Simulations Plus Inc (SLP)?
As of 2026Q1, 432 institutions hold shares of Simulations Plus Inc, with a combined market value of approximately 17.68M, accounting for 87.48% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4627215.00.
What is the biggest source of revenue for Simulations Plus Inc?
In 2026Q1, the Consulting services business generated the highest revenue for Simulations Plus Inc, amounting to 9.54M and accounting for 51.78% of total revenue.